Navigation Links
The Japanese Market For Peripheral Vascular Devices Will Be Characterized By New Product Launches In Many Segments
Date:8/22/2013

TORONTO, Aug. 22, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, efforts to streamline the regulatory approval process in Japan have resulted in the recent entry of numerous devices in the Japanese peripheral vascular (PV) device market, and more products, such as drug-coated balloons and infrapopliteal stents, are expected to enter in the next few years.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO)

The femoropopliteal (fem-pop) stent segment in particular has seen significant activity in the past year. Prior to the approval of the first product in March 2012, procedures using fem-pop stents were only performed off-label; since then, three fem-pop stents have received approval. Cook Medical's Zilver PTX stent was the first to enter the market, and this product also represents the first drug-eluting stent (DES) approved for peripheral indications in Japan. Because this product enjoys a first-to-market advantage, many Japanese physicians continue to prefer it to other fem-pop stents that received later approval.

The aortic stent graft market has also seen a number of recent product approvals, and most new products address previous limitations of aortic stent grafts and will allow a greater number of patients to be treated with these minimally invasive devices. For example, Medtronic's Endurant abdominal aortic stent graft is a low-profile device, providing physicians with a better treatment option for patients with difficult anatomies.

"The availability of these novel devices and the entry of new competitors will help raise the profile of aortic stent graft treatment," said MRG Analyst Tonya Martin. "These developments will encourage more physicians to learn the procedures, and this market will begin to see penetration comparable to Europe."

The Japanese PV device market will, however, be limited by the Ministry of Health, Labour and Welfare (MHLW)'s biennial reimbursement cuts, which will place substantial pressure of PV device prices. MHLW cuts will have the most significant impact on the percutaneous transluminal angioplasty (PTA) balloon catheter market, which will ultimately decline as a result.

Millennium Research Group's Japanese Markets for Peripheral Vascular Devices 2013 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for PV stents, PTA balloon catheters, chronic total occlusion crossing devices, embolic protection devices, inferior vena cava filters, aortic stent grafts, synthetic surgical grafts and PV accessory devices in Japan.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Japanese Heart Valve Device Market Growth Will Spike With The Launch of Transcatheter Heart Valves
2. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
3. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
4. Reimbursement Cuts Will Challenge Japanese Interventional Cardiology Device Market
5. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
6. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
7. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
8. Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine
9. Novartis begins shipment of seasonal influenza vaccines to US market
10. Siemens Healthcare Takes Top Honors in Both Market Shares and Technology, Making it Frost & Sullivans Company of the Year in Interventional Radiology
11. Genomics and Proteomics Reagents, Research Kits and Analytical Instruments Market is Expected to Grow to USD 52.3 Billion Globally by 2019: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... This report provides all the information you ... and activities since 2010. Download the full ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)... 2017   Fourth-quarter 2016 ... $4,010 million to top end of guidance ... impairment charges in fourth-quarter 2016 associated with the write-down ... Company,s Generics reporting unit ... continuing operations; Full-year 2016 reported $14.48 diluted (GAAP) loss ...
(Date:2/27/2017)... Inc. (NYSE: HYH ) today reported fourth quarter ... related key planning assumptions. Executive Summary 2016 fourth ... compared to the prior year. Net income ... net income of $15 million in the fourth quarter of ... to adjusted net income of $27 million in the prior ...
Breaking Medicine Technology:
(Date:2/28/2017)... City, Utah (PRWEB) , ... February 28, 2017 , ... ... is a time for everyone to reaffirm their commitment to improving cardiovascular health for ... of death for men and women. Every year, one in four deaths are caused ...
(Date:2/27/2017)... WI (PRWEB) , ... February 27, 2017 , ... Bo ... Investigator Award. Dr. Chen will receive his award during the Plenary Session at ASLMS ... (ASLMS), to be held in San Diego, California April 5-9, 2017. , During ...
(Date:2/27/2017)... ... 27, 2017 , ... Much attention has been paid to the problem of ... opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain ... overdoses in male populations.(1) , The proportion of women using illicit drugs is also ...
(Date:2/27/2017)... Shenzhen, China (PRWEB) , ... February 26, 2017 , ... ... , This pioneer sound and video system brings songs, movies, TV shows and much ... 3D sound offers clear, high-definition sound. An immersive view of 1280 x 720 provides ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... Francisco and environs, is proud to announce an upgrade to the company's Yelp ... upgraded Yelp page on topics as diverse as Platelet Rich Plasma (PRP) therapy, ...
Breaking Medicine News(10 mins):